Loading clinical trials...
Loading clinical trials...
Phase 2 Trial of Niraparib or Niraparib and Bevacizumab Combination in Patients With Recurrent Endometrial Cancer and/or Ovarian Cancer With ARID1A Mutation (OU-SCC-ARID1A)
Conditions
Interventions
Bevacizumab
Niraparib
Locations
2
United States
University of Oklahoma Health Sciences Center, Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia, United States
Start Date
February 15, 2023
Primary Completion Date
January 8, 2025
Completion Date
January 8, 2025
Last Updated
March 28, 2025
NCT04550494
NCT06349642
NCT05603910
NCT07144826
NCT06855706
NCT06295965
Lead Sponsor
University of Oklahoma
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions